Shelby Saunders

Cooley advised Lovable Labs, a Sweden-based artificial intelligence startup, on its $15 million pre-Series A financing round. The round was led by Creandum, with participation from Visionaries Club and angel investors, including Charlie Songhurst (Meta Platforms board), Adam D’Angelo and Thomas Wolf (Hugging Face), and Erik Bernhardsson (Modal Labs).

Lawyers Kevin Rooney, Karem Jarada, Carl Min, Shelby Saunders, Rebecca Ross, Christopher Kimball and Karen Tsai led the Cooley team advising Lovable, with support from paralegal Chu Lee and transactional quantitative analyst Jake Ironfield.

Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.

Cooley advised Tenable Holdings (Nasdaq: TENB), the exposure management company exposing and closing the cybersecurity gaps that erode business value, on its definitive agreement to acquire Vulcan Cyber, an innovator in exposure management, for $150 million in enterprise value.

Cooley advised Vance Street Capital, a Los Angeles-based middle-market private equity firm that invests in highly engineered solutions businesses across the industrial technology, medical, life sciences, aerospace and defense sectors, on its acquisition of System Seals, a designer and manufacturer of custom fluid seals for various industrial applications.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.